NCT06576115View on ClinicalTrials.gov

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
DRUG

Nab paclitaxel

125 mg/m2 weekly, on days 1,8, and 15 or on days 1 and 15 as a 30-40 minute infusion administered first

DRUG

Gemcitabine

1000 mg/m2 weekly, on day 1,8 and 15 or 1000 mg/m2 weekly, on day 1 and 15 over 30 minutes after nab- paclitaxel infusion

DEVICE

TheraBionic P1

This treatment consists of delivering preset low levels of radio waves into the body with a spoon-shaped antenna placed in the mouth, three times a day, for an hour each time.

Trial Locations (1)

48021

RECRUITING

Karmanos Cancer Institute, Detroit

All Listed Sponsors
lead

Barbara Ann Karmanos Cancer Institute

OTHER